CMV and EBV-specific CD8 T cells persist within the allodepleted CD137^neg cell subset. (A) Of CMV-seropositive healthy donor 724, fresh PBMCs (day 0) and allo-MLC CD8 responder cells (day 22) were stained with anti-CD8 and with anti-CD69, anti-CD137, or IgG isotype control, respectively, followed by incubation with the CMVpp65/A*0201 tetramer. Donor and MLC stimulator cells were matched for HLA-A*0201. Numbers refer to the percentage of positive cells per total CD8 T cells (left) or per gated tetramer^pos CD8 T cells (italics). (B) Of CMV-seropositive healthy donor 837, haploidentical MLTC CD8 responders (day 22) obtained before and after CD137-mediated allodepletion were stained with anti-CD8 and the CMVpp65/B*0702 tetramer. Donor and MLTC stimulator cells were matched for HLA-B*0702. (C) EBV-BMLF1/A*0201 tetramer analysis on day 22 MLTC responders before and after anti-CD137 SAD. The EBV-seropositive healthy donor 203 was matched with haploidentical MLTC stimulator cells for HLA-A*0201. Numbers in panel B and C refer to the percentage of tetramer^pos cells per total CD8 T cells with the isotype control subtracted.